Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

High drug costs. Low drug costs. Each has a price.

Peter Ubel, MD
Meds
January 12, 2015
Share
Tweet
Share

India is not, yet, a wealthy country. Nevertheless its people experience many of the same expensive-to-treat illnesses as wealthier populations in the U.S. and Europe. Therefore, the country has made a series of policy decisions designed to lower the cost of medical treatments.

For example, until 2005, it offered no — I repeat, no — patent protection for pharmaceutical products, thereby spurring the development of its robust and relatively inexpensive generic industry. Even when India passed patent laws in 2005, the laws only offered weak protections. When new drugs come onto the Indian market, they typically face generic competition less than, gulp, 12 months after their launch.

The upside of these policies is straightforward. Drugs in India are cheap, often way less expensive than the cost of the same medications in the U.S. or Europe. But India’s policies create a less obvious, but very important, downside — they delay the entry of new pharmaceutical products into the Indian market. This delay is powerfully rendered in the following figure, reproduced from a study published in Health Affairs, and conducted by Ernst Berndt, an economist at MIT, and Iain Cockburn, a management professor at Boston University:

India-Cost-of-Low-Drug-Prices

The figure shows how quickly new drugs come to market after they receive FDA approval in the U.S., a relatively high regulatory hurdle requiring the kind of scientific evidence that typically meets the standards required by European and Indian regulators too. Within one to two years, most of these products have been launched in the U.S., launches that suggest that the companies believe they can profit from the drugs, thereby justifying the enormous marketing and other costs associated with bringing them to market. Germany does not see quite as many of these drugs come to market so quickly, likely reflecting the lower prices such products demand in that heavily regulated country. But India? It takes almost five years for even half of those products to come to market there. As Berndt and Cockburn put it: “These low prices have arguably come at the cost of significant delays in the availability of new drugs.”

That’s an understatement. There is little doubt that the dismal odds of profiting in India deter pharmaceutical companies from quickly entering that market. But that does not, therefore, mean that India is making a mistake by promoting such stingy policies. India’s approach involves a value judgment, hopefully, a well-thought out one. The Indian government must decide the importance of lowering the price of available drugs, given that such policies will delay how quickly its citizens will get access to new ones. The government has to decide how to balance these two important goals, of controlling costs versus expanding access. India is not wealthy enough to have it all, to be able to pay full price for all the latest treatments while providing medical care to most of its citizens. As its economy grows, I expect India to tighten up its patent laws or to somehow give pharmaceutical companies more incentives to launch products in their markets more quickly.

In the meantime, India’s situation serves as a reminder. Both high and low drug costs come at a price.

Peter Ubel is a physician and behavioral scientist who blogs at his self-titled site, Peter Ubel and can be reached on Twitter @PeterUbel.  He is the author of Critical Decisions: How You and Your Doctor Can Make the Right Medical Choices Together. This article originally appeared in Forbes.

Prev

4 things we can learn from Stuart Scott

January 12, 2015 Kevin 1
…
Next

Treating the influx of marijuana-associated hospital admissions

January 12, 2015 Kevin 11
…

Tagged as: Medications

Post navigation

< Previous Post
4 things we can learn from Stuart Scott
Next Post >
Treating the influx of marijuana-associated hospital admissions

ADVERTISEMENT

More by Peter Ubel, MD

  • Clinicians shouldn’t be punished for taking care of needy populations

    Peter Ubel, MD
  • Patients alone cannot combat high health care prices

    Peter Ubel, MD
  • Is the FDA too slow to handle the pandemic?

    Peter Ubel, MD

More in Meds

  • A psychiatrist’s 20-year journey with ketamine

    Muhamad Aly Rifai, MD
  • How drug companies profit by inventing diseases

    Martha Rosenberg
  • Every medication error is a system failure, not a personal flaw

    Muhammad Abdullah Khan
  • Why kratom addiction is the next public health crisis

    Muhamad Aly Rifai, MD
  • FDA delays could end vital treatment for rare disease patients

    GJ van Londen, MD
  • Pharmacists are key to expanding Medicaid access to digital therapeutics

    Amanda Matter
  • Most Popular

  • Past Week

    • Why your clinic waiting room may affect patient outcomes

      Ziya Altug, PT, DPT and Shirish Sachdeva, PT, DPT | Conditions
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
    • The ethical crossroads of medicine and legislation

      M. Bennet Broner, PhD | Conditions
    • How robotics are transforming the next generation of vascular care [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • How robotics are transforming the next generation of vascular care [PODCAST]

      The Podcast by KevinMD | Podcast
    • The high cost of gender inequity in medicine

      Kolleen Dougherty, MD | Physician
    • Mpox isn’t over: A silent epidemic is growing

      Melvin Sanicas, MD | Conditions
    • How your family system secretly shapes your health

      Su Yeong Kim, PhD | Conditions
    • Women physicians: How can they survive and thrive in academic medicine?

      Elina Maymind, MD | Physician
    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 3 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why your clinic waiting room may affect patient outcomes

      Ziya Altug, PT, DPT and Shirish Sachdeva, PT, DPT | Conditions
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
    • The ethical crossroads of medicine and legislation

      M. Bennet Broner, PhD | Conditions
    • How robotics are transforming the next generation of vascular care [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • How robotics are transforming the next generation of vascular care [PODCAST]

      The Podcast by KevinMD | Podcast
    • The high cost of gender inequity in medicine

      Kolleen Dougherty, MD | Physician
    • Mpox isn’t over: A silent epidemic is growing

      Melvin Sanicas, MD | Conditions
    • How your family system secretly shapes your health

      Su Yeong Kim, PhD | Conditions
    • Women physicians: How can they survive and thrive in academic medicine?

      Elina Maymind, MD | Physician
    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

High drug costs. Low drug costs. Each has a price.
3 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...